News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:
   

Gilead (GILD)’s Best Moves and Biggest Mistake in 2016



12/16/2016 6:43:56 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Enjoying windfall in revenue from its highly successful hepatitis C program in 2015, Gilead Sciences (NASDAQ:GILD) decided to return money to investors via a dividend and share buybacks. As a result, the company's handed back billions of dollars to investors through the first nine months of 2016. But given that Gilead Sciences' sales have fallen 10% and earnings per share have tumbled 14.5% in the past year, is this really the best use of its money.

Read at Motley Fool
Read at News Release
Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES